rs132630290
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP5_Moderate
The NM_000533.5(PLP1):c.3G>A(p.Met1?) variant causes a start lost, splice region change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic (★).
Frequency
Genomes: not found (cov: 23)
Consequence
PLP1
NM_000533.5 start_lost, splice_region
NM_000533.5 start_lost, splice_region
Scores
7
4
3
Splicing: ADA: 0.08381
2
Clinical Significance
Conservation
PhyloP100: 5.73
Genes affected
PLP1 (HGNC:9086): (proteolipid protein 1) This gene encodes a transmembrane proteolipid protein that is the predominant component of myelin. The encoded protein may play a role in the compaction, stabilization, and maintenance of myelin sheaths, as well as in oligodendrocyte development and axonal survival. Mutations in this gene cause Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Alternatively splicing results in multiple transcript variants, including the DM20 splice variant. [provided by RefSeq, Feb 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant X-103776998-G-A is Pathogenic according to our data. Variant chrX-103776998-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 11087.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PLP1 | NM_000533.5 | c.3G>A | p.Met1? | start_lost, splice_region_variant | 1/7 | ENST00000621218.5 | NP_000524.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PLP1 | ENST00000621218.5 | c.3G>A | p.Met1? | start_lost, splice_region_variant | 1/7 | 1 | NM_000533.5 | ENSP00000484450 | P1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD3 genomes
Cov.:
23
GnomAD4 exome Cov.: 27
GnomAD4 exome
Cov.:
27
GnomAD4 genome Cov.: 23
GnomAD4 genome
Cov.:
23
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Hereditary spastic paraplegia 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | This sequence change affects the initiator methionine of the PLP1 mRNA. The next in-frame methionine is located at codon 206. This variant is not present in population databases (gnomAD no frequency). Disruption of the initiator codon has been observed in individuals with PLP1-related conditions (PMID: 8786077, 10417279, 12910435, 22343157). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 11087). For these reasons, this variant has been classified as Pathogenic. - |
Pelizaeus-Merzbacher disease, mild Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 1996 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T;T;T;T;T;T;T;.
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;.;D;D;D;D;D;.;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationTaster
Benign
A;A;A
PROVEAN
Benign
N;.;N;N;N;.;N;.;.
REVEL
Pathogenic
Sift
Uncertain
D;.;D;D;D;.;D;.;.
Sift4G
Uncertain
D;D;D;D;D;D;D;D;D
Polyphen
0.0
.;.;.;.;.;B;.;B;B
Vest4
0.79, 0.80, 0.76
MutPred
Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);Gain of catalytic residue at M1 (P = 0.017);
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
dbscSNV1_RF
Benign
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at